Syncom Formulations (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2025.
SYNCOMF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Syncom Formulations approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025), along with the limited review report from the auditors. The Board also confirmed that the 37th Annual General Meeting will be held on September 29, 2025 at 2:00 PM via video conferencing, and finalized related items like the book closure dates, e-voting cut-off, and appointment of a scrutinizer. Several auditor appointments were cleared, including the secretarial auditor, cost auditor, and internal auditor, most of which need shareholder approval at the upcoming AGM. Major management changes were announced effective August 9, 2025: Kedarmal Bankada was re-designated from Chairman & Whole-time Director to Whole-time Director, Ankit Bankda resigned as CFO but was appointed as the new Chairman & Whole-time Director, Rinki Banka resigned as Whole-time Director, and Rahul Vijay Bankda was appointed as the new CFO. The Board also approved amendments to the company's Memorandum and Articles of Association, subject to shareholder approval.
The most market-relevant item is the Q1 FY26 results approval, which should be released separately with actual numbers and will likely drive the next stock move. The top-level management reshuffle — a new Chairman, a new CFO, and a director exit from the promoter family — is a meaningful governance change that investors should monitor closely for execution and continuity.